Researchers from the University of Oxford, Newcastle University, and the University of Cambridge have identified autoantibodies against interleukin-10 (IL-10) in approximately 3.5% of inflammatory bowel disease (IBD) patients, offering a biological explanation for a genetic marker previously linked to severe disease and pointing toward more targeted treatment strategies.
Background Context
Interleukin-10 is a key regulatory molecule that suppresses inflammation in the gut. When functioning normally, IL-10 acts as a brake on the immune system, preventing excessive inflammatory responses. The discovery that some patients develop autoantibodies capable of blocking IL-10 explains why inflammation becomes uncontrolled in this subset of cases. The genetic variant HLA-DRB1*01:03, which was identified decades ago by Oxford researchers and associated with severe IBD, has now been mechanistically linked to the presence of these anti-IL-10 autoantibodies. This connection strengthens the understanding that IBD is not a single disease, but rather a collection of biologically distinct conditions.
Key Findings
The study, published in the New England Journal of Medicine, analysed samples from more than 4,900 patients with IBD. Anti-IL-10 autoantibodies were detected in around 3.5% of cases, present in both Crohn’s disease and ulcerative colitis cohorts. The researchers demonstrated that when these autoantibodies bind to IL-10, they neutralise its anti-inflammatory function, effectively removing the immune system’s regulatory control. This finding provides a molecular explanation for why certain patients experience particularly severe or treatment-resistant disease. The identification of the HLA-DRB1*01:03 genetic variant as a predictor of autoantibody presence offers a potential biomarker for clinicians to identify patients who may benefit from alternative therapeutic approaches. The researchers emphasised that this discovery enables the classification of a distinct IBD subgroup based on underlying biology rather than clinical presentation alone.
Clinical Relevance
For gastroenterologists and IBD nurses, the identification of anti-IL-10 autoantibodies introduces the possibility of stratifying patients at diagnosis or during treatment evaluation. Rather than relying solely on symptom patterns or endoscopic findings, testing for these autoantibodies could inform decisions about biologic therapy selection and escalation strategies. While the proportion of affected patients is modest, those who carry these autoantibodies may require fundamentally different management approaches. This work supports the broader shift in IBD care toward molecular profiling and precision medicine, aiming to reduce the cycle of trial-and-error prescribing that affects many patients and delays effective treatment.
Reference
University of Oxford, Newcastle University, and University of Cambridge. Autoantibodies against interleukin-10 identified in subset of inflammatory bowel disease patients. N Engl J Med. 2026. Available from: https://www.eurekalert.org
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.